ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

From Startup ARQULE

Link to Full Article: http://investors.arqule.com/news-releases/news-release-details/arqule-report-third-quarter-2018-financial-results-october-31

BURLINGTON, Mass.–(BUSINESS WIRE)–Oct. 17, 2018–
ArQule,
Inc. (Nasdaq: ARQL) today announced it will report financial results for
the third quarter of 2018 before the market opens on Wednesday, October
31, 2018. The Company will hold a conference call and webcast on the
same day at 9:00 a.m. ET to discuss these results and provide a general
business update.

The live webcast can be accessed in the “Investors and Media” section of
our website, www.arqule.com,
under “Events
& Presentations.” You may also listen to the call by dialing
(877) 868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call and
can be accessed in the “Investors & Media” section of our website, www.arqule.com,
under “Events
and Presentations.”

About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet need
that will dramatically extend and improve the lives of our patients. Our
clinical-stage pipeline consists of five drug candidates, all of which
are in targeted, biomarker-defined patient populations, making ArQule a
leader among companies our size in precision medicine. ArQule’s pipeline
includes: ARQ 531, an orally bioavailable, potent and reversible
inhibitor of both wild type and C481S-mutant BTK, in Phase 1 for
patients with B-cell malignancies refractory to other therapeutic
options; Miransertib (ARQ 092), a selective inhibitor of the AKT
serine/threonine kinase, in a Phase 1/2 company-sponsored study for
Overgrowth Diseases, in a Phase 1 study for ultra-rare Proteus syndrome
conducted by the National Institutes of Health (NIH), and in Phase 1b in
combination with the hormonal therapy, anastrozole, in patients with
advanced endometrial cancer; ARQ 751, a next generation AKT inhibitor,
in Phase 1 for patients with AKT1 and PI3K mutations; Derazantinib, a
multi-kinase inhibitor designed to preferentially inhibit the fibroblast
growth factor receptor (FGFR) family, in a registrational trial for
iCCA; and ARQ 761, a β-lapachone analog being evaluated as a promoter of
NQO1-mediated programmed cancer cell necrosis, in Phase 1/2 in multiple
oncology indications in partnership with the University of Texas
Southwestern Medical Center. ArQule’s current discovery efforts are
focused on the identification and development of novel kinase
inhibitors, leveraging the Company’s proprietary library of compounds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005031/en/
Source: ArQule, Inc.
Corporate Contact:ArQule, Inc.Marc Schegerin, M.D.Senior
Vice President/Head of Strategy, Finance and Communicationir@arqule.comorMedia
Contact:LifeSci Public RelationsAllison Blum, Ph.D.,
646-627-8383Allison@lifescipublicrelations.comwww.ArQule.com

Please visit their site for more information: ARQULE.com
All,Biotechnology,Healthcare News
2018-10-18 05:19:34